(UroToday.com) Hispanic American men have an increased incidence of advanced prostate cancer over time. In this study, Dr. Recio-Boiles and colleagues leveraged the National Cancer Database to identify Hispanic American men with prostate cancer and analyzed the association between different groups within this population and rates of metastatic disease and treatment. Hispanic American men were divided into four subgroups: Mexican/Chicano, Puerto Rican, Cuban, and Central/South Americans.
Of the 428,829 Hispanic American and non-Hispanic White patients identified in the database, 5,625 or 1.3% were Hispanic American. Of these 5,625 patients, 51.2% were Mexican. After adjusting for PSA, age, clinical T stage, nodal stage, insurance, income, and education using multivariate analysis, Mexican patients had a statistically significant higher rate of developing metastatic disease compared to non-Hispanic White men (OR 1.32, p = 0.01). These patients also had lower odds (OR 0.68, p < 0.001) for receiving treatment compared to non-Hispanic White men. The authors concluded that despite accounting for some environmental factors such as potential socioeconomic disparities, Mexican men were more likely to develop metastatic disease and not receive treatment for clinically significant prostate cancers (Gleason score >= 7). Whether other unmeasured environmental or biological factors explain these findings warrants further investigation.
Presented by: Alejandro Recio-Boiles MD, Genitourinary Medical Oncologist at the University of Arizona Cancer Center, Tucson, AZ
Written by: Alok K. Tewari, MD, PhD, medical oncologist at Dana-Farber Cancer Institute, @aloktewar on Twitter during the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 – Saturday Feb 19, 2022